Ultragenyx Pharmaceutical
RARE
229 hedge funds and large institutions have $2.76B invested in Ultragenyx Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 89 increasing their positions, 76 reducing their positions, and 26 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
17% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 76
1.08% more ownership
Funds ownership: 96.78% → 97.86% (+1.1%)
0% more funds holding
Funds holding: 228 → 229 (+1)
12% less call options, than puts
Call options by funds: $9.19M | Put options by funds: $10.4M
12% less capital invested
Capital invested by funds: $3.14B → $2.76B (-$387M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$24.5M |
| 3 |
BlackRock
New York
|
+$23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$37M |
| 2 |
Goldman Sachs
New York
|
-$28.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$24.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.7M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$18.6M |
RARE Hedge Fund Activity: Q1 2023 in Review
229 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2023, worth a combined $2.76B — down 12% from $3.14B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RARE positions and 26 closed out — a net gain of 5 holders — while 89 added to existing stakes and 76 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $28.3M. The largest seller was Avidity Partners Management, cutting an estimated $37M.
- 229 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2023, up from 228 in Q4 2022.
- Funds reported $2.76B of Ultragenyx Pharmaceutical stock for Q1 2023, down 12% quarter-over-quarter.
- 31 funds opened new Ultragenyx Pharmaceutical positions in Q1 2023 and 26 closed out, a net change of +5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2023 was Point72 Asset Management, an estimated $28.3M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2023 was Avidity Partners Management, an estimated $37M sold.
Based on aggregated 13F filings for Q1 2023.